A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy

Inactive Expert

Angela Bauer

Professor; Chief, Division Of Gastroenterology; Program Director, Gastroenterology Fellowship

Senior Vice President For Health Affairs, Uf & President, Uf Health

Inactive Expert

Dona-Marie Mintz

Fiscal Manager, Hcv-Target

Professor Of Medicine And Division Chief